The other half received the same aggressive cholesterol-lowering treatment, but their injections contained Repatha. After 48 weeks, their LDL cholesterol had dropped to unprecedented low levels (the ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...

The FDA expanded Repatha's label to include adults at increased risk for MACE due to uncontrolled LDL-C, broadening access beyond those with diagnosed CVD. Repatha is now approved as a standalone ...

* Top-line results from approximately 27,500-patient event-driven fourier study are anticipated in q1 of 2017 Sign up here. * Amgen Inc - "effect of repatha on cardiovascular morbidity and mortality ...

The US Food and Drug Administration (FDA) has approved Amgen's cholesterol-lowering medication, Repatha (evolocumab) injection, a human monoclonal antibody that inhibits proprotein convertase ...

The drug was the first PCSK9 inhibitor approved in Europe and the second approved in the US. FDA announced on Aug. 27, 2015 that it approved Repatha (evolocumab), Amgen’s PCSK9 inhibitor for the ...

Amgen has secured a recommendation for its new cholesterol drug Repatha (evolocumab) from NICE, giving it a major advantage on Sanofi/Regeneron's rival Praluent (alirocumab). NICE rejected any use of ...

Amgen still hopes new cardiovascular data will solve a problem facing cholesterol drug, Repatha – in almost eight out of ten cases US insurers and Medicare initially refuse to prescribe the drug. One ...

Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...